Susceptibility of clinical isolates from Japan to trovafloxacin and other antimicrobial agents

K. Yamaguchi, S. Miyazaki, F. Kashitani, M. Iwatani, N. Watanabe, N. Uehara, T. Sasaki, K. Yoshida, N. Sato, H. Yoshida, Y. Imafuku, K. Wada, J. Igari, T. Oguri, Y. Kobayashi, Y. Katohno, K. Totsuka, J. Shimada, K. Kanemitsu, M. KakuS. Waki, I. Hashizume, K. Yamanaka, T. Matsushima, Y. Niki, N. Miyashita, K. Yoshida, S. Kono, Y. Miyazaki, J. Matsuda, Y. Hirakata, J. Ono, T. Takata, T. Matsunaga, A. Nomura

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The susceptibility of 2,197 clinical isolates in Japan to trovafloxacin and other antimicrobial agents was determined by broth microdilution. Test strains were isolated from 1997 to 1999 from patients with bacterial infections other than urinary tract infections at 14 hospitals in Japan. The activity of trovafloxacin against gram-positive organisms was greater than that of ciprofloxacin, tosufloxacin, sparfloxacin, levofloxacin or cephems. MIC90 of trovafloxacin against methicillin-susceptible Staphylococcus aureus was 0.03 μg/mL, of Streptococcus pyogenes 0.25 μg/mL, of Streptococcus pneumoniae 0.25 μg/mL and Streptococcus agalactiae 0.5 μg/mL. Trovafloxacin exhibited great activity against S. pneumoniae, regardless of penicillin resistance. Although trovafloxacin and other fluoroquinolones exhibited low activity against Enterococcus faecalis and Enterococcus faecium, trovafloxacin (MIC90, 2 μg/mL) was more active against Enterococcus avium than other agents. The activity of trovafloxacin (MIC90s, 0.12 to 1 μg/mL) against Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter aerogenes, Proteus vulgaris, and Morganella morganii was comparable to or greater than that of cephems and imipenem. Trovafloxacin and other fluoroquinolones (MIC90s, ≤0.015 to 0.06 μg/mL) exhibited great activity against Moraxella catarrhalis and Haemophilus influenzae. Fluoroquinolones (MIC90s, 4 to 8 μg/mL) including trovafloxacin were more active against Pseudomonas aeruginosa than other agents. Trovafloxacin was the most active against Bacteroides fragilis with an MIC90 of 2 μg/mL.

Original languageEnglish
Pages (from-to)241-256
Number of pages16
JournalJapanese Journal of Chemotherapy
Volume49
Issue number4
Publication statusPublished - 2001 Jun 13

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Susceptibility of clinical isolates from Japan to trovafloxacin and other antimicrobial agents'. Together they form a unique fingerprint.

  • Cite this

    Yamaguchi, K., Miyazaki, S., Kashitani, F., Iwatani, M., Watanabe, N., Uehara, N., Sasaki, T., Yoshida, K., Sato, N., Yoshida, H., Imafuku, Y., Wada, K., Igari, J., Oguri, T., Kobayashi, Y., Katohno, Y., Totsuka, K., Shimada, J., Kanemitsu, K., ... Nomura, A. (2001). Susceptibility of clinical isolates from Japan to trovafloxacin and other antimicrobial agents. Japanese Journal of Chemotherapy, 49(4), 241-256.